MVA85A

Jump to navigation Jump to search

WikiDoc Resources for MVA85A

Articles

Most recent articles on MVA85A

Most cited articles on MVA85A

Review articles on MVA85A

Articles on MVA85A in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on MVA85A

Images of MVA85A

Photos of MVA85A

Podcasts & MP3s on MVA85A

Videos on MVA85A

Evidence Based Medicine

Cochrane Collaboration on MVA85A

Bandolier on MVA85A

TRIP on MVA85A

Clinical Trials

Ongoing Trials on MVA85A at Clinical Trials.gov

Trial results on MVA85A

Clinical Trials on MVA85A at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on MVA85A

NICE Guidance on MVA85A

NHS PRODIGY Guidance

FDA on MVA85A

CDC on MVA85A

Books

Books on MVA85A

News

MVA85A in the news

Be alerted to news on MVA85A

News trends on MVA85A

Commentary

Blogs on MVA85A

Definitions

Definitions of MVA85A

Patient Resources / Community

Patient resources on MVA85A

Discussion groups on MVA85A

Patient Handouts on MVA85A

Directions to Hospitals Treating MVA85A

Risk calculators and risk factors for MVA85A

Healthcare Provider Resources

Symptoms of MVA85A

Causes & Risk Factors for MVA85A

Diagnostic studies for MVA85A

Treatment of MVA85A

Continuing Medical Education (CME)

CME Programs on MVA85A

International

MVA85A en Espanol

MVA85A en Francais

Business

MVA85A in the Marketplace

Patents on MVA85A

Experimental / Informatics

List of terms related to MVA85A


MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the old TB vaccine called BCG.[1] Phase I clinical trials have been completed and phase II clinical trials are currently underway in South Africa with the aim of achieving a product licence by 2010.[2]

External links

References

  1. McShane H, Pathan AA, Sander CR; et al. (2004). "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-mycrobial immunity in humans". Nat Med. 10: 1240&ndash, 44.
  2. Ibanga H, Brookes R, Hill P, Owiafe P, Fletcher H, Lienhardt C, Hill A, Adegbola R, McShane H (2006). "Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design". Lancet Infect Dis. 6 (8): 522–8. PMID 16870530.


Template:WikiDoc Sources